A phase I trial of CORT118335 for non-alcoholic fatty-liver disease and other metabolic disorders.
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs CORT 118335 (Primary)
- Indications Metabolic disorders; Non-alcoholic fatty liver disease
- Focus Adverse reactions
- 01 Aug 2017 According to a Corcept Pharmaceuticals media release, this trial is expected to begin this month.
- 08 Feb 2017 New trial record